ArticleAdvances in radiation oncology2026
Encouraging Local Control With Pediatric Spatially Fractionated Radiation Therapy.
Article in Advances in radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Spatially fractionated radiation therapy (SFRT) is a promising treatment involving the delivery of discrete spheres of high-dose radiation, potentially enhancing treatment response. Despite encouraging results for adult patients, no SFRT data exist in pediatric patients. Methods and Materials: All pediatric patients receiving radiation therapy from 2019 to 2025 with at least 1 follow-up imaging study were considered. Patient characteristics and outcomes were recorded via institutional review board-approved retrospective chart review. Results: Five pediatric patients who received SFRT were identified, with a median age of 15.7 years (range, 6.5-17.2 years). Three were alive at last follow-up (median, 13 months; range, 3-18 years). Neither tumor progression nor grade ≥ 2 toxicity was identified at SFRT sites. One recurrent wound infection occurred after enoxaparin sodium injection in the high-dose radiation therapy field. Two patients received upfront SFRT for pelvic osteosarcoma, followed by 74.8 Gy in 34 fractions and 69 Gy in 30 fractions. The treatment volume was over 600 cm Conclusions: We present one of the first case series of SFRT in pediatric patients, with favorable local control and toxicity results. Further study of SFRT for radioresistant or recurrent tumors is required.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.